Investing in stocks is a big key to long-term wealth and prosperity. But you need to know the basics of the stock market to be a good investor.
In the following video, Dan Caplinger, the Motley Fool's director of investment planning, discusses three key facts about the stock market. Dan examines three different ways to categorize stocks and points out some of the advantages and disadvantages of each group of stocks. Specifically, in discussing the historical edge that small-cap stocks have over large caps, he looks at the example of the energy industry and the struggles that oil giants ExxonMobil (NYSE:XOM) and Chevron (NYSE:CVX) have in keeping their production levels up, even as small up-and-coming exploration and production companies produce huge growth.
Dan goes on to examine the value-versus-growth debate, using the recent struggles of Intuitive Surgical (NASDAQ:ISRG) as a way to highlight the challenges high-growth stocks face when their growth inevitably falters. Finally, Dan talks about international stocks, noting that the long-term performance of the iShares MSCI EAFE ETF (NYSEMKT:EFA) is very close to the domestic SPDR S&P 500 (NYSEMKT:SPY), but that the two often produce different returns year-to-year, providing some diversification.
Fool contributor Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Chevron and Intuitive Surgical and owns shares of Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Oil Stocks to Buy Right Now
Oil prices are at multiyear highs, but these three companies are set to profit whether they go higher or not. Here's why they're worth buying now.
Earnings: 2 Hot Stocks to Watch Next Week
These two stocks have soared in the past 12 months. Can they continue to impress investors?
Here's How Intuitive Surgical, Inc. Crushed It in 2017
2017 was a banner year for the leader in robotic surgery. Look and see why investors couldn't have asked for much more.